Analysts Set Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Price Target at $178.93

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has received a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $178.9333.

Several research firms have recently weighed in on JAZZ. Truist Financial increased their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective for the company. Morgan Stanley increased their price objective on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Saturday, September 27th. Finally, The Goldman Sachs Group increased their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th.

Jazz Pharmaceuticals Trading Down 0.2%

Shares of JAZZ stock opened at $137.32 on Friday. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The business’s 50 day moving average is $124.57 and its two-hundred day moving average is $115.63. The company has a market cap of $8.33 billion, a PE ratio of -20.40, a price-to-earnings-growth ratio of 8.45 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter last year, the business earned $5.30 EPS. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts predict that Jazz Pharmaceuticals will post 16.96 EPS for the current year.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares of the company’s stock, valued at $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 11,500 shares of company stock valued at $1,525,280 over the last three months. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hurley Capital LLC bought a new position in Jazz Pharmaceuticals in the first quarter worth $25,000. Parallel Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 119 shares during the period. Spire Wealth Management lifted its holdings in shares of Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 161 shares during the period. Picton Mahoney Asset Management lifted its holdings in shares of Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 269 shares during the period. Finally, SVB Wealth LLC bought a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $36,000. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.